Please login to the form below

Not currently logged in
Email:
Password:

Catabasis hires Rick Modi as its chief business officer

Will help the firm develop its flagship Duchenne muscular dystrophy product

The US biotech firm Catabasis Pharmaceuticals has named Rick Modi as its new chief business officer. 

Modi brings to Catabasis 15 years of experience in corporate, business and product commercialisation strategy.

Jill Milne, co-founder and chief executive of Catabasis, said: “Rick has valuable experience across multiple brands, including orphan drug positioning, commercialisation and marketing. 

“We look forward to leveraging his capabilities as we advance our clinical development pipeline, particularly CAT-1004 for Duchenne muscular dystrophy (DMD), and our lipid programmes, CAT-2003 and CAT-2054.”

Modi added: “Catabasis has a novel approach to drug development that allows for simultaneous modulation of multiple targets in a disease pathway, and I am privileged to join this team as we seek to bring disease-modifying treatments to patients with DMD or severe lipid disorders."

Prior to joining Catabasis, Modi was senior vice president, global marketing at InterMune - an orphan drug company that was acquired by Roche late last year.

He played a large role in the launch of InterMune's flagship product, the lung-scarring drug Esbriet (pirfenidone)

Modi has also held roles of increasing responsibilities in corporate strategy, new product planning and sales and marketing at AstraZeneca's biologics arm MedImmune as well as J&J's subsidiary Centocor.

16th February 2015

From: Research, Healthcare

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Frontera Group

Welcome to Frontera Group, where our agencies immerse you in the world of the patient...

Latest intelligence

The other side of … rheumatoid arthritis
For Georgie, patient activation fuelled her motivation to find life without pain. So when blood tests came back normal, she felt confident to pursue referral until RA was confirmed......
How to lessen site burden with a targeted patient recruitment strategy
Picture this: you’ve created your patient recruitment strategy and you find more and more patients are undertaking the pre-screening, you probably think – success! But then you find out, getting...
Peter Howarth
Exploring the potential of eosinophils
GSK’s Peter Howarth talks about the emerging research that suggests there is a varied role for eosinophils...

Infographics